## Amendments to the Claims

Claims 1-20. (Cancelled)

21. (Currently Amended) A compound selected from the group consisting of:

4-[5-(Phenethylamino-methyl)-thiophen-2-yloxy]-benzamide

4-{5-[(3-Methyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide

4-(5-{[2-(3-Fluoro-phenyl)-ethylamino]-methyl}-thiophen-2-yloxy)-benzamide

4-{5-[(2-Cyclopentyl-ethylamino)-methyl]-thiophen-2-yloxy}-benzamide

4-{5-[(2-Thiophen-2-yl-ethylamino)-methyl]-thiophen-2-yloxy}-benzamide

4-{5-[(3,3-Dimethyl-butylamino)-methyl]-thiophen-2-yloxy}-benzamide

 ${\it 3-Methoxy-4-[5-(phenethylamino-methyl)-thiophen-2-yloxy]-benzamide $$\frac{hydroehloride}{}$$ 

 $3-Methoxy-4-\{5-[(3-methyl-butylamino)-methyl]-thiophen-2-yloxy\}-benzamide \\ \frac{1}{2} + \frac{1}{2}$ 

3

4-[5-(2-Phenethylamino-ethyl)-thiophen-2-yloxy]-benzamide-hydrochloride

$$\text{CONH}_2$$

 $5\hbox{-}\{4\hbox{-}[(3\hbox{-}Ethylpentylamino)methyl] phenoxy} thiophene-2\hbox{-}carboxamide$ 

2-{4-[(3-Methylbutylamino)methyl]phenoxy}thiazole-5-carboxamide

2-(4-{[2-(Tetrahydropyran-4-yl)ethylamino] methyl}phenoxy)thiazole-5-carboxamide methanesulfonate

and aor a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer or diastereomerie mixture thereof.

- (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula IClaim 21 in association with a carrier, diluent and/or excipient.
  - 23. (Cancelled)
  - 24. (Cancelled)
  - 25. (Cancelled)
  - 26. (Cancelled)
  - 27. (Cancelled)
  - 28. (Cancelled)